Exposure to wild-type AAV drives distinct capsid immunity profiles in humans
Open accessThe DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Abstract
Recombinant adeno-associated virus (AAV) vectors have been broadly adopted as a gene delivery tool in clinical trials, owing to their high efficiency of transduction of several host tissues and their low immunogenicity. However, a considerable proportion of the population is naturally exposed to the WT virus from which AAV vectors are derived, which leads to the acquisition of immunological memory that can directly determine the outcome of gene transfer. Here, we show that prior exposure to AAV drives distinct capsid immunity profiles in healthy subjects. In peripheral blood mononuclear cells (PBMCs) isolated from AAV-seropositive donors, recombinant AAV triggered TNF-α secretion in memory CD8+ T cells, B cell differentiation into antibody-secreting cells, and anti-capsid antibody production. Conversely, PBMCs isolated from AAV-seronegative individuals appeared to carry a population of NK cells reactive to AAV. Further, we demonstrated that the AAV capsid activates IL-1β and IL-6 cytokine secretion in monocyte-related dendritic cells (moDCs). IL-1β and IL-6 blockade inhibited the anti-capsid humoral response in vitro and in vivo. These results provide insights into immune responses to AAV in humans, define a possible role for moDCs and NK cells in capsid immunity, and open new avenues for the modulation of vector immunogenicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“More recent work has highlighted the role of innate immune system in response to AAV therapeutics (42–46)”
From Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood (2022) · cites this paper as [43]
In the citing paper
“Adaptive anti-capsid humoral [27] and cytotoxic [28, 29] immune responses have been shown to be restricted in vivo by inhibiting innate immune activation pathways.”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [27]
In the citing paper
“Studies suggest that following secondary AAV exposure, capsid-specific memory T cells produce cytokines and acquire a cytotoxic phenotype [27, 106–108].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [27]
In the citing paper
“moDCs have been previously identified as the main cells secreting IL-6 and IL-1β in response to AAV in human blood (43)”
From Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood (2022) · cites this paper as [43]
In the citing paper
“Although Kuranda et al. showed induction of pro-inflammatory cytokines IL-6 and IL-1b upon exposure of human PBMCs with empty AAV capsid, they did not directly implicate TLR2 for this pro-inflammatory milieu.”
From Innate immune sensing of adeno-associated virus vectors (2024) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986 · cited 1×
“These cells showed increased TNF-α and granzyme B secretion and signs of recent activation/exhaustion, indicated by PD-1 upregulation (41).”
BackgroundOf Mice and Not Men: Differences between Mouse and Human Immunology
Mestas, J., & Hughes, C. C. W. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.2731 · Cited by 3,822 · cited 2×
“Additionally, in mice, the TLR2 expression pattern and regulation are different (70) and, unlike in humans (13), anti-AAV antibody formation in mice is TLR2 independent (21).”
BackgroundSingle-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 9×
“Our study supports this hypothesis, as it shows that CD8+ T cells restimulated with the VP1372–380 epitope (22) secrete cytotoxic granules (CD107a) in the presence of target cells, without concomitant IFN-γ secretion.”
BackgroundMethodInfluentialSelf-citationRussell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952 · cited 1×
“org Volume 128 Number 12 December 2018 Introduction With several successful adeno-associated virus (AAV) vector– based gene therapy clinical trials (1–4) and the recent approval by the FDA of a gene therapy for congenital blindness (5), the promise of a definitive cure for numerous genetic diseases is becoming a reali…”
BackgroundAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Self-citationNovel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 1×
“We used the AAV8 serotype, which is highly homologous to AAV2 (49) but has a greater capacity to transduce murine hepatocytes (50).”
MethodLong-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Self-citationHuman NK Cell Education by Inhibitory Receptors for MHC Class I
Anfossi, N., André, P., Guia, S., Falk, C. S., Roetynck, S., Stewart, C. A., Breso, V., Frassati, C., Reviron, D., Middleton, D., et al. (2006) · Immunity · doi:10.1016/j.immuni.2006.06.013 · Cited by 1,211 · cited 1×
“Indeed, these cells are prominent innate immune effectors known to rapidly respond to infection without prior sensitization and are activated by target cells rather than by the sole presence of cytokines (75).”
BackgroundBoutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970 · cited 1×
“The ICS assays performed ex vivo or after 1 cycle on AAV2, as it naturally infects humans and is therefore the most seroprevalent of all AAV serotypes (44).”
BackgroundSelf-citation
Research works printed but not linked: 1
- 10.1016/j.cellimm.2017.07.12 · doi:10.1016/j.cellimm.2017.07.12
Cited by
Items 101–104 of 104
Etude des réponses T CD8+ après transfert de gène par rAAV ciblant le muscle
Jeanpierre, L. (2024) · theses.fr (ABES) · doi:10.70675/430aceacz50d2z426bz907dz876c55d1e935
Smesnik, G., Virgolini, N., Dürauer, A., & Borth, N. (2026) · Biotechnology Journal · doi:10.1002/biot.70282
“In addition, rAAVs exhibit a comparatively favorable safety profile, characterized by generally low immunogenicity upon first administration [10–14] and a predominantly non‑integrating behavior of the vector genome [5, 15].”
Baatartsogt, N., Batchuluun, K., Kashiwakura, Y., Amarbayasgalan, M., Nordog, M., Altangerel, O., Otgonbayar, P., Tegshee, U., Batjargal, K., Togashi, T., et al. (2026) · Human Gene Therapy · doi:10.1177/10430342261459805
“20,21 Importantly, the high prevalence and multiserotype reactivity of NAbs suggest that a substantial proportion of individuals in Mongolia may not meet the current eligibility criteria for AAV-based gene therapy, highlighting important considerations for clinical implementation.”
MADCAP: isolation of novel nAb-naïve AAV capsids from metagenomic data
Lyashenko, E., Torregrosa, T., Ysasi, A. B., Wu, J. T., Bu, J., Hennessy, M., Na, Y., Ryan, M. J., Takar, M., Manek, R., et al. (2026) · Journal of Virology · doi:10.1128/jvi.00630-26 · Cited by 1
“CTL responses limit the expression of therapeutic transgenes and can induce cytotoxic tissue damage (32–35).”
Metadata
- Authors
- Kuranda, K., Jean-Alphonse, P., Leborgne, C., Hardet, R., Collaud, F., Marmier, S., Costa Verdera, H., Ronzitti, G., Veron, P., & Mingozzi, F.
- Affiliations
- Inserm (FR)
- Genethon (France) (FR)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2018-10-22
- Volume
- 128
- Issue
- 12
- Pages
- 5267-5279
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6264647
- OpenAlex
- W2897401411
- Cited by
- 104
- References
- 79
- Citations by year
- 2026: 6 · 2025: 11 · 2024: 13 · 2023: 11 · 2022: 18 · 2021: 16 · 2020: 17 · 2019: 11 · 2018: 1
- FWCI
- 6.90
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- E-Rare
- European Commission (667751, FP7-PEOPLE-2012-CIG, 333628, 617432)
- Institut National de la Santé et de la Recherche Médicale
- Centre International de Mathématiques et Informatique de Toulouse
- FP7 People: Marie-Curie Actions (FP7-PEOPLE-2012-CIG)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus vectors, memory CD8+ T cells, natural killer cells, monocyte-derived dendritic cells, IL-1β, interleukin-6, TNF-α, humoral immune response, vector immunogenicity, gene therapy
- MeSH terms
- Dependovirus, Adolescent, Adult, Aged, Aged, 80 and over, Capsid, Cell Line, Dendritic Cells, Female, Genetic Vectors, Humans, Immunologic Memory, Lymphocytes, Male, Middle Aged, Genetic Therapy, Interleukin-6, Gene Transfer Techniques, Interleukin-1beta, Immunity, Humoral
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.